KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Accounts Payables (2017 - 2025)

Historic Accounts Payables for Moderna (MRNA) over the last 9 years, with Q3 2025 value amounting to $267.0 million.

  • Moderna's Accounts Payables fell 2841.82% to $267.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $267.0 million, marking a year-over-year decrease of 2841.82%. This contributed to the annual value of $405.0 million for FY2024, which is 2211.54% down from last year.
  • Per Moderna's latest filing, its Accounts Payables stood at $267.0 million for Q3 2025, which was down 2841.82% from $175.0 million recorded in Q2 2025.
  • Moderna's 5-year Accounts Payables high stood at $520.0 million for Q4 2023, and its period low was $8.0 million during Q1 2021.
  • Moreover, its 5-year median value for Accounts Payables was $279.0 million (2024), whereas its average is $278.5 million.
  • In the last 5 years, Moderna's Accounts Payables skyrocketed by 238750.0% in 2022 and then tumbled by 5295.63% in 2024.
  • Moderna's Accounts Payables (Quarter) stood at $302.0 million in 2021, then skyrocketed by 61.26% to $487.0 million in 2022, then rose by 6.78% to $520.0 million in 2023, then fell by 22.12% to $405.0 million in 2024, then plummeted by 34.07% to $267.0 million in 2025.
  • Its last three reported values are $267.0 million in Q3 2025, $175.0 million for Q2 2025, and $226.0 million during Q1 2025.